Search Results - "Bajaj, J S"

Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis by Bajaj, J. S.

“…Summary Background Progressive gut milieu (microbiota) changes occur in patients with cirrhosis and are associated with complications [e.g. hepatic…”
Get full text

Review article: the modern management of hepatic encephalopathy by BAJAJ, J. S.

“…Aliment Pharmacol Ther 31, 537–547 Summary Background  Hepatic encephalopathy, both overt and minimal, forms a continuum of cognitive change in cirrhosis…”
Get full text

Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement by Bajaj, J. S., Cordoba, J., Mullen, K. D., Amodio, P., Shawcross, D. L., Butterworth, R. F., Morgan, M. Y.

“…Aliment Pharmacol Ther 2011; 33: 739–747 Summary Background  The clinical classification of hepatic encephalopathy is largely subjective, which has led to…”
Get full text

Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis by Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., Puri, P., Sterling, R. K., Luketic, V., Stravitz, R. T., Siddiqui, M. S., Fuchs, M., Thacker, L. R., Wade, J. B., Daita, K., Sistrun, S., White, M. B., Noble, N. A., Thorpe, C., Kakiyama, G., Pandak, W. M., Sikaroodi, M., Gillevet, P. M.

“…Summary Background Safety of individual probiotic strains approved under Investigational New Drug (IND) policies in cirrhosis with minimal hepatic…”
Get full text

Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis by Bajaj, J. S., Ratliff, S. M., Heuman, D. M., Lapane, K. L.

“…There is increasing evidence that proton pump inhibitors (PPIs) increase the rate of infections in patients with decompensated cirrhosis. To estimate the…”
Get full text

Predictors of the recurrence of hepatic encephalopathy in lactulose‐treated patients by BAJAJ, J. S., SANYAL, A. J., BELL, D., GILLES, H., HEUMAN, D. M.

“…Aliment Pharmacol Ther 31, 1012–1017 Summary Background  Lactulose is considered first‐line therapy for hepatic encephalopathy. However, the effect of…”
Get full text

Statin use and infections in Veterans with cirrhosis by Motzkus‐Feagans, C., Pakyz, A. L., Ratliff, S. M., Bajaj, J. S., Lapane, K. L.

“…Summary Background Evidence about the beneficial effects of statins on reducing infections is accumulating. Identifying ways to reduce infection risk in…”
Get full text

PROMIS computerised adaptive tests are dynamic instruments to measure health‐related quality of life in patients with cirrhosis by Bajaj, J. S., Thacker, L. R., Wade, J. B., Sanyal, A. J., Heuman, D. M., Sterling, R. K., Gibson, D. P., Stravitz, R. T., Puri, P., Fuchs, M., Luketic, V., Noble, N., White, M., Bell, D., Revicki, D. A.

“…Aliment Pharmacol Ther 2011; 34: 1123–1132 Summary Background  Cirrhotic patients have an impaired health‐related quality of life (HRQOL), which is usually…”
Get full text

Non‐selective beta‐blockers are not associated with serious infections in veterans with cirrhosis by Bajaj, J. S., Ratliff, S. M., Heuman, D. M, Lapane, K. L.

“…Summary Background Studies evaluating outcomes associated with non‐selective beta‐blockers (NSBB) in cirrhosis have yielded mixed results. A major cause of…”
Get full text

Modified-orientation log to assess hepatic encephalopathy by Salam, M., Matherly, S., Farooq, I. S., Stravitz, R. T., Sterling, R. K., Sanyal, A. J., Gibson, D. P., Wade, J. B., Thacker, L. R., Heuman, D. M., Fuchs, M., Puri, P., Luketic, V., Bickston, S. J., Bajaj, J. S.

“…Summary Background The subjectivity of the West‐Haven criteria (WHC) hinders hepatic encephalopathy (HE) evaluation. The new HE classification has emphasised…”
Get full text

Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis by Acharya, C., Betrapally, N. S., Gillevet, P. M., Sterling, R. K., Akbarali, H., White, M. B., Ganapathy, D., Fagan, A., Sikaroodi, M., Bajaj, J. S.

“…Summary Background Opioid use is epidemic in cirrhosis, which could precipitate hepatic encephalopathy (HE) potentially through gut dysbiosis and inflammation…”
Get full text

Editorial: patient‐reported outcomes in chronic HCV—a PROMISing approach to an ongoing problem by Acharya, C., Bajaj, J. S.

“…Linked Content This article is linked to Evon et al and Evon papers. To view these articles visit https://doi.org/10.1111/apt.14531 and…”
Get full text

Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients? by Shaw, J., Bajaj, J. S.

“…Linked Content This article is linked to Cole et al paper. To view this article visit https://doi.org/10.1111/apt.13827…”
Get full text

Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes by Wong, F, O'Leary, J G, Reddy, K R, Garcia-Tsao, G, Fallon, M B, Biggins, S W, Subramanian, R M, Thuluvath, P J, Kamath, P S, Patton, H, Maliakkal, B, Tandon, P, Vargas, H, Thacker, L, Bajaj, J S

“…The International Ascites Club (IAC) recently defined Stage 1 acute kidney injury (AKI) for cirrhosis as an acute increase in serum creatinine (SCr) by ≥0.3…”
Get full text

Postoperative management of noniatrogenic traumatic bile duct injuries : role of endoscopic retrograde cholangiopancreaticography by BAJAJ, J. S, SPINELLI, K. S, DUA, K. S

“…Endoscopic therapy for iatrogenic bile duct injuries is well established. Abdominal trauma-related biliary injuries, however, are complex in nature. The role…”
Get full text

Commentary: probing probiotics in cirrhosis – a template for future studies? Author's reply by Bajaj, J. S.

Get full text

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients by Bajaj, J. S., Sterling, R. K., Betrapally, N. S., Nixon, D. E., Fuchs, M., Daita, K., Heuman, D. M., Sikaroodi, M., Hylemon, P. B., White, M. B., Ganapathy, D., Gillevet, P. M.

“…Summary Background Eradication of hepatitis C virus (HCV) is increasing but its residual impact on the pro‐inflammatory milieu in cirrhosis, which is…”
Get full text

Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation by Bhutta, A. Q., Garcia‐Tsao, G., Reddy, K. R., Tandon, P., Wong, F., O'Leary, J. G., Acharya, C., Banerjee, D., Abraldes, J. G., Jones, T. M., Shaw, J., Deng, Y., Ciarleglio, M., Bajaj, J. S.

“…Summary Background It has been suggested that beta‐blockers may increase mortality in patients with cirrhosis and refractory ascites but the effect of…”
Get full text

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis by Bajaj, J. S., Barrett, A. C., Bortey, E., Paterson, C., Forbes, W. P.

“…Summary Background Rifaximin therapy reduced risk of hepatic encephalopathy (HE) recurrence and HE‐related hospitalisations during a 6‐month, randomised,…”
Get full text

Commentary: TIPSS for Budd‐Chiari syndrome by Dharel, N., Bajaj, J. S.

Get full text